Company intelligence / Profile preview

Proveca

Manchester, England, United Kingdommedicines.ie ↗

Ownership: Private
Development stage: Commercial

Overview

Proveca specializes in developing and licensing medicines tailored to the unmet medical needs of children, particularly focusing on neurology and cardiology. Its lead product, Sialanar™, addresses chronic pathological drooling and has received Paediatric Use Marketing Authorisation (PUMA) for use across Europe. The company works closely with clinicians, regulators, and families to bring age-specific formulations to market. Proveca has been recognized as a finalist at the Reuters Events Pharma Awards EU 2024 for its medical education initiatives.

Therapeutic areas: Neurology
Modalities: Small molecules (e.g., Sialanar™ is a reformulation of an existing medicine)
Industry: Biotech

Drug pipeline

3 assets

PRO-N-02

Unknown

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Proveca.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proveca.

Explore the full profile